ARCH Venture Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/ARCH Venture Partners/Activity

ARCH Venture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Co-led CREATE Medicines' $122M Series B to advance its in vivo CAR pipeline in autoimmune disease and oncology; Senior Partner Brian Cuneo joined the board.

CREATE Medicines

CREATE Medicines ARCH Venture Partners

biopharmadive.comMAY 14, 2026

MAY 14, 2026

Milestone

Paradigm Health partnered with the FDA on a real-time clinical trial monitoring platform.

Paradigm Health

Paradigm Health ARCH Venture Partners

archventure.comAPR 2026

APR 2026

3 newss· FEB 2026 – APR 2026Show all

News

ARCH partner Carol Suh was honored on the San Francisco Business Times 40 Under 40 Class of 2026.

Carol Suh named to San Francisco Business Times 40 Under 40

ARCH Venture Partners

archventure.comAPR 2026

bizjournals.com

APR 2026

News

ARCH's Carol Suh was named to NVCA's 2026 Rising Stars list.

Carol Suh named to NVCA 2026 Rising Stars list

ARCH Venture Partners

linkedin.comFEB 19, 2026

FEB 19, 2026

News

ARCH's Carol Suh was named to the National Venture Capital Association's 2026 List of Rising Stars.

Carol Suh named to NVCA 2026 List of Rising Stars

ARCH Venture Partners

archventure.comFEB 2026

FEB 2026

Investment

Participated as an existing investor in Mirador Therapeutics' $250M Series B for its immuno-fibrotic disease pipeline.

Mirador Therapeutics

Mirador TherapeuticsARCH Venture Partners

businesswire.comJAN 12, 2026

JAN 12, 2026

Investment

Participated as an existing investor in Parabilis Medicines' oversubscribed $305M Series F to advance zolucatetide toward Phase 3.

Parabilis Medicines

Parabilis Medicines ARCH Venture Partners

biopharmadive.comJAN 8, 2026

JAN 8, 2026

Exit

D-Wave Quantum acquired ARCH-backed Quantum Circuits to accelerate quantum computer development.

Quantum Circuits

Quantum CircuitsARCH Venture Partners

archventure.comJAN 2026

barrons.com

JAN 2026

Exit

Pfizer acquired ARCH-backed Metsera in $10 billion deal to accelerate obesity drug development.

Metsera

Metsera ARCH Venture Partners

archventure.comNOV 2025

endpoints.news

NOV 2025

Investment

Participated in Kardigan's $254M Series B to advance its late-stage portfolio of personalized cardiovascular medicines.

Kardigan

Kardigan ARCH Venture Partners

businesswire.comOCT 14, 2025

OCT 14, 2025

Exit

Bristol Myers Squibb acquired ARCH-backed Orbital Therapeutics and its In Vivo RNA platform.

Orbital Therapeutics

Orbital Therapeutics ARCH Venture Partners

archventure.comOCT 2025

endpoints.news

OCT 2025

News

TIME and Statista recognized ARCH as a top U.S. venture firm.

TIME and Statista top U.S. venture firm recognition

ARCH Venture Partners

archventure.comAUG 2025

AUG 2025

Investment

Co-founded and led the $216M Series A launch of Dispatch Bio, a universal CAR-T solid tumor immunotherapy company, alongside the Parker Institute for Cancer Immunotherapy.

Dispatch Biotherapeutics

Dispatch Biotherapeutics ARCH Venture Partners

statnews.comJUL 23, 2025

JUL 23, 2025